FDA approves first novel PD-1 developed in China; US trial to come post-approval

Oct 31

Written By Team Rxtrospect

Team Rxtrospect

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

RxTROSPECT, Inc 2025 — All rights reserved. “RxTROSPECT” refers to RxTROSPECT, Inc.. RxTROSPECT, Inc. is an intelligence company offering a range of data and analytics products through its partnerships with Tableau, LLC (a subsidiary of Salesforce, Inc), and Mango Technologies, Inc. dba ClickUp.

Testimonials are specific to an individual Customer’s experience and may not be representative of all Customers. Unless otherwise indicated, Customers offering a Testimonial do not receive compensation and their statement does not present a conflict of interest.

RxTROSPECT is not affiliated with, sponsored, or endorsed by the companies listed, described, or featured on its site. Company logos or trademarks used do not imply endorsement and are the property of their respective owners.

This is a representative list of customers that work with RxTROSPECT as of January 1st, 2025. It is not known whether they approve or disapprove of our products.

FDA approves first novel PD-1 developed in China; US trial to come post-approval

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

European approval for AbbVie's TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

solutions

ABOUT US

RESOURCES